文献速递贫血与红细胞疾病

促炎状态促进镰状细胞病患儿红细胞同种免疫

Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease.
PubMed 文献 · Blood Adv · 2023-01-01

研究分析471例镰状细胞病患儿红细胞同种免疫的危险因素,55例(11.70%)发生同种免疫,形成59种同种抗体和17种自身抗体。促炎事件期间输血者同种抗体形成比例为23.8%(30/126单位),稳定状态为2.8%(27/952单位),促炎事件期间输血增加同种免疫风险(OR 4.22,95%CI 1.64-10.85,P=.003)。

要点

  • 471例患儿中55例(11.70%)发生同种免疫,同种免疫率为每100单位0.36种同种抗体
  • 促炎事件期间输血同种抗体形成23.8%(30/126单位)vs 稳定状态2.8%(27/952单位)
  • 作者认为促炎事件期间审慎使用输血对预防同种免疫至关重要

核心结论

  • 输血受者的炎症状态影响红细胞同种免疫风险,且该风险不受羟基脲治疗改变。
  • 作者认为促炎事件期间审慎使用输血对预防同种免疫至关重要。

研究设计与样本

  • 研究纳入471例镰状细胞病患儿,分析输血时受者炎症状态及羟基脲抗炎作用相关的同种免疫危险因素。

主要发现

  • 471例中55例(11.70%)发生同种免疫,形成59种同种抗体和17种自身抗体,同种免疫率为每100单位0.36种同种抗体。
  • 27例形成明确特异性同种抗体者中,促炎事件期间输注单位同种抗体形成为23.8%(30/126),稳定状态输注单位为2.8%(27/952)。
  • 促炎事件期间输血增加同种免疫风险(OR 4.22,95%CI 1.64-10.85,P=.003)。
  • 接受间歇性输血(多为促炎事件期间)患者的同种免疫未因羟基脲治疗(OR 6.52,95%CI 0.85-49.77,P=.071)、羟基脲疗程(OR 1.13,95%CI 0.997-1.28,P=.056)或羟基脲剂量(OR 1.06,95%CI 0.96-1.16,P=.242)而降低。
  • 高输血负荷(OR 1.02,95%CI 1.003-1.04,P=.020)及HbSS与HbSβ0-地中海贫血基因型(OR 11.22,95%CI 1.51-83.38,P=.018)为同种免疫的其他危险因素。

临床怎么用

  • 作者认为促炎事件期间审慎使用输血对预防同种免疫至关重要。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We examined risk factors for red blood cell (RBC) alloimmunization in pediatric patients with sickle cell disease, focusing on the recipients' inflammatory state at the time of transfusion and anti-inflammatory role of hydroxyurea (HU). Among 471 participants, 55 (11.70%) participants were alloimmunized and formed 59 alloantibodies and 17 autoantibodies with an alloimmunization rate of 0.36 alloantibodies per 100 units. Analysis of 27 participants in whom alloantibodies were formed with specificities showed 23.8% (30/126) of units transfused during a proinflammatory event resulting in alloantibody formation compared with 2.8% (27/952) of units transfused at steady state. Therefore, transfusion during proinflammatory events increased the risk for alloimmunization (odds ratio [OR], 4.22; 95% confidence interval [CI], 1.64-10.85; P = .003). Further analysis of all the 471 participants showed that alloimmunization of patients who received episodic transfusion, mostly during proinflammatory events, was not reduced with HU therapy (OR, 6.52; 95% CI, 0.85-49.77; P = .071), HU therapy duration (OR, 1.13; 95% CI, 0.997-1.28; P = .056), or HU dose (OR, 1.06; 95% CI, 0.96-1.16; P = .242). The analysis also identified high transfusion burden (OR, 1.02; 95% CI, 1.003-1.04; P = .020) and hemoglobin S (HbSS) and HbSβ0-thalassemia genotypes (OR, 11.22, 95% CI, 1.51-83.38; P = .018) as additional risk factors for alloimmunization. In conclusion, the inflammatory state of transfusion recipients affects the risk of RBC alloimmunization, which is not modified by HU therapy. Judicious use of transfusion during proinflammatory events is critical for preventing alloimmunization.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Gossett JM, Chen PL, et al. Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease. Blood Adv. 2023. PMID: 37023228. doi:10.1182/bloodadvances.2022008647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。